During a double-blind study of two years' cytotoxic chemotherapy with busulphan or cyclophosphamide in patients who had had resection of carcinoma of the bronchus the long-term effects of these two drugs were also studied. Four of the 243 patients treated with busulphan developed leukaemia compared with none of the 234 treated with cyclophosphamide and none of the 249 on placebo. None of these four patients received radiotherapy or other cytotoxic chemotherapy before leukaemia was diagnosed, and all four were among the 19 patients who developed pancytopenia while taking busulphan, five to eight years before leukaemia became clinically apparent.
Introduction
Acute leukaemia has been reported after the long-term administration of melphalan in patients with multiple myelomal 3 and also after the use of other cytotoxic drugs for treating carcinoma. '-7 A large-scale double-blind investigation of over 700 patients was undertaken by a Medical Research Council working party in 1965 to discover whether busulphan and cyclophosphamide delayed or even prevented the recurrence of bronchial carcinoma after the surgical removal of all visible intrathoracic growth.
This presented an opportunity to study the long-term effects of these two cytotoxic drugs, particularly the likelihood of their inducing leukaemia.
Patients and methods
There were 726 patients with bronchial carcinoma in the study, all of whom had had all visible intrathoracic growth resected.`Immediately after operation the patients were allocated at random to receive daily treatment with busulphan, cyclophosphamide, or placebo. The tablets were indistinguishable, and the study was conducted doubleblind throughout the two years of treatment and the subsequent follow-up, neither the patient nor the doctor in charge knowing which agent had been allocated. For the first 10 days of treatment all patients received eight tablets once a day (one tablet of busulphan was equi-valent to 0 5 mg and one of cyclophosphamide to 25 mg). Thereafter they received six tablets daily as maintenance chemotherapy. Because of an unexpectedly high incidence of toxicity from the cytotoxic drugs, however, this dose was halved about 11 months after the start of the study to three tablets daily for all three regimens. Altogether 243 patients received busulphan (B series), 234 received cyclophosphamide (C series), and 249 received placebo (P series).
Total leucocyte and platelet counts and haemoglobin concentrations were estimated every month during the first two years and subsequently only when requested by the doctor. The maintenance dose was controlled monthly by the doctor from the results of regular monthly blood investigations and the dose was reduced when haematological toxicity was suspected, particularly thrombocytopenia (defined as a fall in the platelet count below 100 x 109/1), leucopenia (a fall in the total leucocyte count below 3 0 x 109/1), or anaemia (a fall in the haemoglobin concentration below 9 gldl). If all three occurred the condition was defined as pancytopenia. These definitions have also been used in this report.
Each patient's general condition was reported on by the doctor every month during the first three years, then every three months to five years, and yearly thereafter.
Results

INCIDENCE OF LEUKAEMIA
No patient in anv series developed leukaemia in the first five years after the start of treatment. By nine years, however, three cases of myelomonocytic leukaemia (in the 62nd, 63rd, and 64th months) and one case of erythroleukaemia (in the 97th month) had been diagnosed, all from among the 69 patients who received busulphan and who were still alive at five years (an incidence of 5 8" ). None of the 63 five-year survivors who received cyclophosphamide or the 85 who received placebo developed leukaemia.
PATIENTS WITH LEUKAEMIA
The details of the four patients who developed leukaemia are shown in figs 1 to 4. The main morphological findings (reported by D A G G) are set out below.* Case 1-At 10 months the marrow was cellular with adtive normoblastic and macronormoblastic erythropoiesis; the megakaryocytes were scanty and most were small forms. At 64 months a marrow biopsy showed that the haemopoietic tissue was almost replaced by poorly differentiated cells including immature granulocytes, an appearance consistent with a diagnosis of acute myelomonocytic leukaemia.
Case 2-At 64 months blood films showed morphological abnormalities in the platelets, granulocytes, and red cells; there was an absolute monocytosis of up to 6 5 10',/I, basophilia of up to 1-7 ,10'/1, and neutrophilia with a high proportion of unsegmented forms. Megakaryocyte fragments, undifferentiated blast cells (up to 2 1 x 10'/l), promyelocytes, myelocytes, and normoblasts were present. The bone marrow was hypercellular and showed an excess of promyelocytes, mvelocytes, and blast cells. The neutrophil alkaline phosphatase score was normal (70). Karyotype analysis was not carried out, but the morphological features suggested an atypical chronic myclomonocytic leukaemia in transformation rather than chronic granulocytic leukaemia in transformation.
Case 3-The histological picture of the marrow after death was that of a monocytic or myelomonocytic variant of acute myeloid leukaemia with destruction of the normal pattern of haemopoiesis and heavy infiltration of the marrow with abnormal monocytic cells.
Case 
with different histology; the remaining two patients (1 B, 1 P) had epitheliomas. One patient (in series B) had primary cancers of the caecum and pelvic colon, another (in series B) cancers of the bladder and opposite lung with different histology, and a third (in series P) cancers of the colon and prostate. erythroleukaemia had typical marrow changes two and a half years after starting treatment with busulphan and more than six years before there was clinical evidence of disease. Busulphan also causes prolonged hypoplasia in mice10 and rats,'" and if it can induce a permanent genetic change in the stem cell"2 the attempts of a hypoplastic marrow to repair itself might lead to the emergence and proliferation of an abnormal clone of cells."3 14
A hypothesis of a direct leukaemogenic effect of busulphan must explain the restriction of leukaemia to patients who experienced prolonged pancytopenia even though the patients who did not experience pancytopenia received similar or even larger total doses of busulphan. This suggests a non-specific effect of the drug, its role being no more than that of a marrowdestructive agent. That potentially malignant cell clones can emerge in marrow stem cells generating from a hypoplastic state, however induced, is suggested by the variety of causes of prolonged hypoplasia that has been followed, usually several years after apparent recovery, by the development of acute myeloid leukaemia. These include ionising radiation,"5--l7 benzene,'8-2 chloramphenicol,21 and phenylbutazone, 2 23 and the same sequence has occurred in idiopathic aplastic anaemia.2' 2-The peak incidence of leukaemia was between five and nine years, but some cases occurred within five years and later than 15 years. A specific leukaemogenic effect of busulphan would, however, have to be invoked if it could be shown that the incidence of leukaemia in patients who recover from busulphaninduced bone-marrow hypoplasia is higher than that in patients with hypoplasia from other causes. Four cases of leukaemia occurred among the eight pancytopenic patients who survived five years, which seems to be a high proportion; the incidence among patients with aplastic anaemia who survived beyond three years and who developed a clone of paroxysmal-nocturnalhaemoglobinuria cells was only 10" (S M Lewis, personal communication), but no reliable figures are available for the incidence of leukaemia in patients who have recovered from hypoplastic anaemia.
Alternative explanations for busulphan's leukaemogenic action cannot altogether be discounted. The immunosuppressive action of the drug may induce leukaemia. No specific tests were done to assess immunological competence in this study. But it is lymphomas rather than acute leukaemias that are more common after immunosuppression for transplantation. If lung cancer itself predisposes to leukaemia while busulphan and busulphaninduced pancytopenia do not, the distribution of the leukaemic cases in the three series should have been similar. But all four cases occurred in the busulphan series; the probability of this occurring by chance is 1 in 27, and the likelihood of all the cases occurring among the 19 pancytopenic patients in the busulphan series is as small as 1 in 50 000. A further possibility is that busulphan activates a leukaemogenic virus or releases one from immunological control.
Although no case of leukaemia has so far occurred among the patients treated with cyclophosphamide in this study, the disease may follow the treatment of malignant neoplasms with this drug.1 3 7 26 In some cases marrow hypoplasia occurred, but most of these patients had also received other cytotoxic drugs or radiotherapy. Nevertheless, cyclophosphamide given in larger doses and for longer periods than in this study has caused acute leukaemia in patients with non-malignant disease who received no other radiotherapy or cytotoxic treatment and who did not in general develop marrow hypoplasia.27-21 The malignant change may have resulted from the immunosuppressive effect of the drug, allowing either the emergence and multiplication of a malignant clone of cells or the escape of a leukaemogenic virus from immunological control. But the same argument against this hypothesis applies as was stated above in the case of busulphannamely that there is a lack of association between leukaemia and other immunodeficiency states, whether these are idiopathic or drug-induced.
The nature of the leukaemogenic action of cyclophosphamide may or may not be the same as that of busulphan. The absence of leukaemia in the cyclophosphamide series of the present study may merely reflect the absence of any case of pancytopenia among the five-year survivors. Alternatively, the association of leukaemia with prolonged exposure to cyclophosphamide without the occurrence of marrow hypoplasia may indicate a different, and possibly more specific, leukaemogenic mechanism for this drug. Cyclophosphamide, like melphalan'-3 and chlorambucil3" but unlike busulphan, might have a mutagenic effect that confers a risk of malignant transformation even in the absence of growth-impeding damage to the stem cells.
All the surviving patients in the study have now been followed up for at least nine years and are being clinically examined 
